Russell Investments Group Ltd. grew its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 84.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 199,590 shares of the company's stock after acquiring an additional 91,201 shares during the quarter. Russell Investments Group Ltd. owned about 0.15% of Vaxcyte worth $7,537,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in PCVX. Parallel Advisors LLC lifted its position in shares of Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after acquiring an additional 1,071 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Vaxcyte by 376.4% in the first quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock valued at $62,000 after acquiring an additional 1,306 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Vaxcyte by 10.9% in the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock valued at $112,000 after acquiring an additional 293 shares in the last quarter. J.Safra Asset Management Corp lifted its position in shares of Vaxcyte by 65.8% in the first quarter. J.Safra Asset Management Corp now owns 3,161 shares of the company's stock valued at $119,000 after acquiring an additional 1,254 shares in the last quarter. Finally, GF Fund Management CO. LTD. lifted its position in shares of Vaxcyte by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 3,192 shares of the company's stock valued at $121,000 after acquiring an additional 575 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Separately, Cowen restated a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $136.50.
Check Out Our Latest Analysis on Vaxcyte
Vaxcyte Stock Performance
NASDAQ PCVX traded up $0.38 during trading hours on Friday, hitting $32.29. 1,519,128 shares of the company's stock were exchanged, compared to its average volume of 1,369,275. The business's 50 day moving average is $33.64 and its 200-day moving average is $44.41. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06. The firm has a market capitalization of $4.19 billion, a P/E ratio of -7.86 and a beta of 1.21.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period in the previous year, the firm posted ($1.10) earnings per share. As a group, equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.
About Vaxcyte
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Further Reading
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access